

Experienced Management Team

An experienced team with a track record of advancing novel therapeutics from bench to clinic and executing complex capital markets transactions.

- J. Roderick Matheson, CEO. 40 years capital markets experience; led financings exceeding \$1B
- Dr. Mark Williams, President & CSO 20+ years drug development; 50+ patents; inventor of DM199 (Phase III, FDA Fast Track)
- Harry Nijjar CPA CMA, CFO public biotech finance and reporting

Scientific Advisory Board

- David Blum, PhD - INSERM, Lille Neuroscience & Cognition
- Jared Young, PhD - University of California San Diego
- Bruce N. Cronstein, MD - NYU Grossman School of Medicine
- Frank Schweizer - University of Manitoba

Business Model

Marvel's business model is to advance MB-204 through clinical trials and resulting value inflection points to be monetized via strategic partnering or M&A. We are executing on multiple paths, including financial and strategic investments, co-development collaborations, and additional non-dilutive funding - and welcome partnership conversations at any stage of development.


About Marvel



Publicly traded: TSXV: MRVL | OTCQB: MBCOF


Developing Therapies for Neuropsychiatric and Neurodegenerative Disorders

Marvel Biosciences Corp. is a clinical-stage CNS company advancing MB-204, a first-in-class structurally optimized adenosine A2A receptor antagonist designed to restore the social reward circuit - a shared biological driver across many diverse neuropsychiatric and neurodegenerative disorders. Marvel is focusing on monogenic orphan diseases including Rett syndrome and Fragile X.




- AUTISM SPECTRUM DISORDER**
~60M patients
\$10B-\$20B+ market
- DEPRESSION**
~280M patients
\$15B-\$25B market
- ALZHEIMER'S DISEASE**
~30M patients
\$20B+ market

MB-204: Best-in-Class Profile vs. Istradefylline



- ✓ Composition-of-matter patents issued: US, China and Japan (other jurisdictions pending)
- ✓ Pediatric liquid formulations developed (F% 79 and 91%) - addresses dysphagia issue
- ✓ Lower dose needed for non-Parkinson's Disease indications - improved safety


MB-204: First-in-Class Profile for Autism, Depression and Alzheimer's Disease



- ✓ **Autism:** MB204 normalizes social and repetitive behaviour in 1 hour - no apparent tolerance
- ✓ **Depression:** MB204 reduces depressive symptoms 1 hour post oral dosing - clinical evidence
- ✓ **Alzheimer's:** MB204 acutely reduces GSK3b activity and Tau hyperphosphorylation (esp AT8)

Phase 1-Ready: Major Development Risks Removed & Early Readouts in SAD

- ✓ cGMP drug product manufactured and released
- ✓ 4-week GLP toxicology complete in rats and dogs with confirmed acceptable safety margins
- ✓ Phase 1 SAD biomarker strategy: ERG b-wave amplitude + Emotional Bias Task + Psychomotor Vigilance Test



Obesity (2013) 5:976-980
J. Neurodev. Dis. (2022) 14:30